Medical technology company Zeltiq Aesthetics Inc. (ZLTQ) said today that it received expanded clearance from the U.S. Food and Drug Administration for its CoolMini applicator, which is designed to treat so-called double chins, and small pockets of fat.
The company said that its CoolSculpting procedure has been shown to reduce unwanted fat in over 50 published clinical articles and 4,000 clinical trial patients.
“Through our continued introduction of new applicators together with expanded clearances from the FDA, we are successfully addressing additional problem areas for our customers,” said Zeltiq CEO Mark Foley in a statement. “I have been particularly pleased with the very positive feedback we are receiving from both physicians and patients based on our limited European launch.”
In Wednesday’s pre-market trading, shares of Zeltiq Aesthetics were up 0.71% to $35.53, moving within a 52-week range of $20.54 – $38.49.
Companies: ZELTIQ Aesthetics, Inc.
Price: 35.53 Price Change: +0.25 Percent Change: +0.71
